Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence

Journal of Cardiovascular Medicine
Marcello DisertoriGISSI-AF Investigators

Abstract

The possibility of preventing atrial fibrillation recurrence with anti-arrhythmic agents is very limited, given the discouraging results obtained with current drugs in many patients. Data from experimental studies suggest that angiotensin II AT1-receptor blockers can influence atrial remodelling, a key factor in atrial fibrillation initiation and maintenance. Moreover, some preliminary clinical data show that angiotensin II AT1 -receptor blockers can prevent atrial fibrillation episodes. The GISSI-Atrial Fibrillation (AF) trial is a randomized, prospective, parallel group, placebo-controlled, multicentre study designed to test whether angiotensin II AT1-receptor blockers can reduce atrial fibrillation recurrence. The primary objective of the study is to demonstrate that, in patients with a history of recent atrial fibrillation who are treated with the best recommended therapies, the addition of the angiotensin II AT1-receptor blocker valsartan (titrated up to 320 mg) is superior to placebo in reducing atrial fibrillation recurrence. A substudy will analyse the effect of valsartan on left atrial dimensions and on neurohormones. The study population consists of patients with symptomatic atrial fibrillation (at least two electroca...Continue Reading

References

Apr 29, 1982·The New England Journal of Medicine·W B KannelP M McNamara
May 12, 1998·The American Journal of Cardiology·G E KochiadakisP E Vardas
Jun 10, 2000·Chest·K J NikulaC Hobbs
Nov 18, 2000·Circulation·D A Cooley, O H Frazier
Jun 14, 2002·Cardiovascular Research·Maurits AllessieUlrich Schotten
Mar 26, 2003·Journal of the American College of Cardiology·Allison M PritchettMargaret M Redfield
Jun 25, 2003·Journal of the American College of Cardiology·Koichiro KumagaiKeijiro Saku
Aug 17, 2004·American Heart Journal·Eugene Braunwald
Aug 17, 2004·American Heart Journal·Peter Sleight
Aug 17, 2004·American Heart Journal·Paul W ArmstrongUNKNOWN VIGOUR group
Aug 17, 2004·American Heart Journal·Luigi TavazziUNKNOWN GISSI

❮ Previous
Next ❯

Citations

Aug 18, 2006·Cardiovascular Drugs and Therapy·Aldo P Maggioni
Mar 5, 2008·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Maya GuglinAnne B Curtis
May 7, 2009·The Canadian Journal of Cardiology·Nadia A KhanUNKNOWN Canadian Hypertension Education Program
Jul 31, 2009·The New England Journal of Medicine·Marcelle D Smit, Isabelle C Van Gelder
Apr 17, 2009·The New England Journal of Medicine·Marcello DisertoriGianni Tognoni
Mar 15, 2011·The American Journal of Bioethics : AJOB·Edward L Korn, Boris Freidlin
May 14, 2009·Vascular Health and Risk Management·Alessandra Del FiorentinoRoberto Pedrinelli
Sep 1, 2006·Future Cardiology·Simone MuscoPeter R Kowey
Dec 30, 2008·Cardiology Clinics·Emily L ConwayPeter R Kowey
Nov 8, 2015·Cardiovascular Drugs and Therapy·Lidia StaszewskyUNKNOWN on the behalf of the GISSI-AF Investigators
Dec 7, 2007·The Medical Clinics of North America·Simone MuscoPeter R Kowey
Sep 11, 2008·British Journal of Clinical Pharmacology·Giuseppina NovoSalvatore Novo
Oct 23, 2010·Journal of Internal Medicine·R LatiniUNKNOWN GISSI-AF Investigators
May 16, 2009·Drugs·Joachim R Ehrlich, Stanley Nattel
Sep 20, 2011·Circulation. Cardiovascular Imaging·Lidia StaszewskyUNKNOWN GISSI-AF Investigators
Jun 14, 2008·Journal of Hypertension·Giuliano TocciMassimo Volpe
Jun 7, 2006·Current Opinion in Cardiology·David H BirnieJeffrey S Healey
Aug 24, 2010·Journal of Cardiovascular Medicine·Ornella DurinGiuseppe Inama
Aug 6, 2005·European Heart Journal·Paolo VerdecchiaGian Paolo Reboldi
May 27, 2009·Expert Opinion on Pharmacotherapy·Silvia BarraGiovanni Gaeta
Oct 5, 2007·Revista española de cardiología·UNKNOWN Grupo de Trabajo para el Tratamiento de la Hipertensión Arterial de la Sociedad EuropeaJosé Luis Zamorano
Nov 21, 2021·BMC Cardiovascular Disorders·Lidia StaszewskyRoberto Latini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.